Mitsubishi Phase 3 EPP Trial Sites Open
?Active study sites now include:
MT-7117 Clinical Trial
Phase 3 Clinical Trial
Participants with EPP or XLP are needed!
Trial Description: A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, And Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).
Treatment: Oral medication (pills), once daily in the morning with or without food Duration: 26 weeks plus optional 26 week double-blinded extension.
Endpoint: Increased pain free light exposure in adults and adolescents with a history of phototoxic reactions from EPP or XLP.
Study Sites: There will be 12 study sites in the US, followed by global study sites across multiple countries.
Age Range: Patients age 12 - 75
Travel: Will be included and will be arranged by a concierge service trained on EPP/XLP.
Please contact the American Porphyria Foundation for more information and we will connect you with a study site nearest you.
Email firstname.lastname@example.org OR
call 866-APF-3635 (301-347-7166).